DAXOR CORPORATION - CLOSED END FUND

Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors

21 Jan 2022 08:00:00 By Nasdaq GlobeNewswire

Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022

20 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

06 Jan 2022 08:00:03 By Nasdaq GlobeNewswire

DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19

05 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

04 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

16 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care

09 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee

01 Oct 2021 08:30:00 By Nasdaq GlobeNewswire

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

14 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100® Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021

08 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

07 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

01 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021

30 Aug 2021 08:30:00 By Nasdaq GlobeNewswire

Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

04 Aug 2021 08:30:00 By Nasdaq GlobeNewswire

DAXOR CORPORATION ANNOUNCES NON-GOVERNMENT DISTRIBUTION AGREEMENT WITH CONCORDANCE® HEALTHCARE SOLUTIONS

22 Jul 2021 08:30:01 By Nasdaq GlobeNewswire

American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

13 Jul 2021 08:30:00 By Nasdaq GlobeNewswire

Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021

28 May 2021 08:30:00 By Nasdaq GlobeNewswire

Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

13 May 2021 08:30:00 By Nasdaq GlobeNewswire

Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100® (Blood Volume Analyzer) with the United States Department of Veterans Affairs

06 May 2021 08:30:02 By Nasdaq GlobeNewswire

Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

29 Apr 2021 08:31:27 By Nasdaq GlobeNewswire